PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

The description of a patent should “always” be used to interpret the claims (DexCom v Abbott, UPC_CFI_230/2023)

  • Technology: Biotechnology, Pharmaceuticals
  • 22nd February 2025
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

This post is based on a previous article on IPKat.

The Paris Local Division of the Unified Patent Court (UPC)’s first substantive decision on patent validity in DexCom v Abbott (UPC_CFI_230/2023), provides some interesting commentary on how much the description should be taken into account when interpreting the claims. Claim interpretation is the subject of the highly anticipated referral to the EPO’s Enlarged Board of Appeal, G1/24 . In DexCom v Abbott, the Paris Local Division followed the approach taken in previous UPC decisions, namely finding that the description should always be consulted when interpreting the claims.  

Case Background

The case involved DexCom, a US company specialising in continuous glucose monitoring systems, and Abbott, a global healthcare group. DexCom’s European patent EP3435866 related to an analyte monitoring system for measuring glucose levels in diabetes patients.

The patent claimed a system comprising a sensor configured to take analyte measurements, a sensor electronics unit, and a display device. A key feature of the system was the use of two different communication protocols, a Bluetooth/BLE for transmitting a first portion of measurement data, and NFC/RFID for transmitting a second portion in response to a data request command.

DexCom alleged infringement by Abbott’s FreeStyle Libre 2 products. Abbott challenged the validity of the patent through a counterclaim for revocation, whilst the main validity dispute focused on whether the claimed dual-protocol system was obvious over the prior art.

 The patent in question had previously been opposed, and the opposition rejected with no appeal filed. 

Claim interpretation: The description and drawings must always be considered

The Local Division first addressed the issue of claim interpretation, adopting the standard set by the UPC Court of Appeal that “the patent claim is not only the starting point, but the decisive basis for determining the protective scope of the European patent” (para. 4.2).

The Local Division adopted the claim interpretation standard set by two previous UPC Court of Appeal decisions, establishing five key principles for balancing patent protection with legal certainty. As noted by the Local Division, the Court of Appeal had previously found that: “The patent claim is not only the starting point, but the decisive basis for determining the protective scope of the European patent.” (para. 4.2).  Following this lead, the Local Division agreed that interpretation of the claims also “does not depend solely on the strict, literal meaning of the wording used” as “the description and the drawings must always be used as explanatory aids” (paragraph 4.2, quoting UPC_CoA_335/2023). In other words, for the Local Division it is necessary to examine both the claim language and the description in order to interpret the claims. The Local Division also emphasises that the principles of claim interpretation apply uniformly to infringement and validity assessments. 

Applying these principles to the case in question, the Local Division addressed the specific disputes over claim interpretation, particularly regarding the meaning of what constituted “first” and “second” portions of the measurement data. Abbott had argued during EPO opposition proceedings that DexCom had adopted a narrow interpretation of “portion” requiring: (1) two distinct portions of data using different protocols, and (2) neither portion could contain all the data. Abbott claimed DexCom was now taking a broader view in litigation because Abbott’s FreeStyle Libre 2 transmitted “the same analyte measurement data” using both protocols, resulting in “total overlap” (para. 4.6).

Applying its principles of claim interpretation, the Division looked to the description to understand the terms used in the claims. The Division agreed with Abbott that “portions of data are not comparable to parts of a book or portions of a cake” (para. 4.7). In contrast to cake, the Local Division found that while “portions” of data could overlap and contain some of the same data, they also could not be identical. For the Local Division, this would contradict both the usual distinction between “first” and “second” portions and the description’s reference to “a portion of the analyte data… and another portion.” The Local Division’s interpretation therefore relied on both the ordinary meaning of “portion” and the distinction made in the description of the patent between “a portion” and “all” data. 

Inventive step

On inventive step, the Local Division found that the prior art disclosed most features of the claimed system, with the only difference being that it did not expressly specify using NFC/RFID as the second protocol. Critically, the Division’s definition of portions as being able to overlap but not be identical, meant that the prior art was interpreted as possessing this feature. The Local Division instead determined the core inventive concept as being whether using NFC as the second protocol was obvious.

The Local Division concluded the choice of NFC would have been obvious to a skilled person, noting that the prior art “expressly discloses that the device 120 already uses NFC for the request command initiating the transmission of the second portion, meaning that the user has already brought the device 120 into close proximity with the device 102. It would therefore be obvious for the skilled person to continue using the same protocol, namely the second near-field communication protocol NFC, to transmit the data and achieve the effects commonly ascribed to this protocol.” (para. 23.7)

The Local Division was unconvinced by DexCom’s arguments regarding technical difficulties or synergistic effects. It found that selecting NFC as the second protocol would have been a routine choice given its well-known advantages of low power consumption and security due to limited range.

The Local Division therefore revoked the patent in its entirety across all designated UPC states, also dismissing DexCom’s infringement claims and auxiliary requests to amend the patent. DexCom was ordered to bear the costs of the proceedings.

Final thoughts

The Paris Division in UPC_CFI_230/2023 follows the lead of other divisions and the Court of Appeal of the UPC in finding that the claims of a patent should be understood in the context of the patent as a whole. In UPC_CoA_335/2023, for example, the Court of Appeal similarly found that the description “must always be used as explanatory aids for the interpretation of the patent claim and not only to resolve any ambiguities in the patent claim” . By contrast, the EBA has indicated in its preliminary opinion that it believes the description “can” be referred to for the purposes of claim interpretation . It will be interesting to see how and if any divergence emerges between the EBA and the UPC on this highly contentious issue, and whether the EBA takes the decisions of the UPC into account when tackling the questions of G1/24. 

Related insights...

Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Post-published clinical data does not always save you (T 0251/25, Empagliflozin)

  • 3rd November 2026
Empagliflozin (Jardiance) is approved in the US for reducing the risk of cardiovascular death in adults with type 2 diabetes (T2D) and established cardiovascular disease, and in Europe for reducing the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure. The recent decision in T 0251/25 nonetheless found Boehringer Ingelheim’s…
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Reformatio in peius survives a procedural violation (T 1168/24)

  • 2nd November 2026
Sometimes patent law is about procedures and not inventions. The appeal in T 1168/24 related to the lipid nanoparticle (LNP) technology behind the COVID-19 vaccines, opposed by Merck and Moderna. After two rounds of opposition and two appeals, the patent was revoked for added matter. Whilst the global litigation surrounding LNPs is interesting in its…
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

The enablement paradox and the danger of definitions (Wyeth v AstraZeneca)

  • 6th October 2026
The Federal Circuit’s decision in Wyeth v AstraZeneca (No. 2024-2325) applied the enablement test to a dose invention. The case is an interesting contrast to the other recent case to apply enablement to a method of treatment claim, Teva v Eli Lilly.
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image

Lack of clarity by the backdoor: An ambiguity “may simply result in a broader interpretation” (T 0977/25)

  • 4th October 2026
In T 0977/25, a Board of Appeal found that the word “it” in an amended method claim for an e-cigarette cartridge was ambiguous.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

G1/25: What are the consequences?

  • 12th September 2026
Following the release of G1/25, questions have been circling as to what the decision means for the pending referral in G 1/26 and what the consequences (good or bad) are for applicants and patentees.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

BREAKING: When real doubt hits – G1/25 changes the description adaptation requirement for the worse

  • 4th September 2026
G 1/25, issued today, holds that the description must be adapted only where an “inconsistency” between the claims and description causes non-compliance with another requirement of the EPC.
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image

New referral on claim interpretation and relevance of G1/24 to added matter confirmed (G1/26)

  • 23rd July 2026
We now have confirmation of a new referral to the EBA on claim interpretation (G1/26). As previously hinted, the Board of Appeal in T 0873/24 has decided to refer questions on the application of G1/24 to the assessment of added matter.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.

When do you file for a drug combination invention? (T 592/24)

  • 16th July 2026
Drug combination inventions are increasingly difficult to protect. File too early for a drug-combination invention and the application may lack the data to support the non-obvious effect of the combination. Wait for the trial read-out, and a competitor, or your own published protocol, may have already placed the invention in the public domain. 
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.

Patenting the use of medical devices (T 0941/24)

  • 26th June 2026
Patenting medical devices in Europe is challenging. First, there is the problem that medical use claims are not permitted for medical devices, whilst simultaneously methods of treatment or surgery using a device are excluded from patentability. 
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image

BREAKING: Imminent new referral to the EBA on the relevance of G1/24 to added matter

  • 6th May 2026
The Board of Appeal in T 873/24 has decided to refer questions to the Enlarged Board of Appeal (EBA) on the application of G1/24 (claim interpretation) to the assessment of added matter.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice